/
/
/

Jubilant Pharmova Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹2229 Cr₹2290 Cr₹2123 Cr₹1966 Cr₹1901 Cr₹1929 Cr₹1822 Cr₹1752 Cr₹1732 Cr₹1759 Cr₹1677 Cr₹1680 Cr₹1587 Cr₹1678 Cr₹1553 Cr₹1600 Cr₹1452 Cr₹1528 Cr₹1311 Cr₹1657 Cr₹1635 Cr₹1580 Cr₹1771 Cr₹1591 Cr₹1156 Cr₹1569 Cr₹1518 Cr₹2266 Cr₹2182 Cr₹2386 Cr₹2377 Cr₹2269 Cr₹2079 Cr₹2252 Cr₹2068 Cr₹1642 Cr₹1596 Cr₹1641 Cr₹1492 Cr₹1419 Cr₹1454 Cr₹1516 Cr₹1367 Cr₹1452 Cr₹1446 Cr₹1537 Cr₹1445 Cr₹1371 Cr₹1473 Cr₹1562 Cr₹1444 Cr₹1437 Cr₹1359 Cr₹1393 Cr₹1306 Cr₹1222 Cr
₹20 Cr₹24 Cr₹21 Cr₹10 Cr₹12 Cr₹12 Cr₹9 Cr₹22 Cr₹14 Cr₹14 Cr₹36 Cr₹10 Cr₹9 Cr₹4 Cr₹10 Cr₹13 Cr₹11 Cr-₹3 Cr₹6 Cr₹4 Cr₹4 Cr₹7 Cr₹4 Cr₹3 Cr₹4 Cr₹17 Cr₹3 Cr₹12 Cr₹10 Cr-₹7 Cr₹29 Cr₹4 Cr₹9 Cr₹23 Cr₹3 Cr₹7 Cr₹7 Cr₹11 Cr₹5 Cr₹5 Cr₹4 Cr₹2 Cr₹3 Cr₹4 Cr₹4 Cr₹6 Cr₹6 Cr₹26 Cr₹4 Cr₹5 Cr₹4 Cr₹4 Cr₹6 Cr₹5 Cr₹12 Cr₹3 Cr
₹2249 Cr₹2314 Cr₹2143 Cr₹1976 Cr₹1913 Cr₹1941 Cr₹1831 Cr₹1774 Cr₹1746 Cr₹1773 Cr₹1713 Cr₹1690 Cr₹1596 Cr₹1682 Cr₹1562 Cr₹1613 Cr₹1463 Cr₹1525 Cr₹1316 Cr₹1662 Cr₹1639 Cr₹1586 Cr₹1775 Cr₹1595 Cr₹1160 Cr₹1586 Cr₹1521 Cr₹2278 Cr₹2192 Cr₹2379 Cr₹2406 Cr₹2273 Cr₹2088 Cr₹2275 Cr₹2071 Cr₹1649 Cr₹1603 Cr₹1652 Cr₹1497 Cr₹1424 Cr₹1458 Cr₹1518 Cr₹1370 Cr₹1456 Cr₹1450 Cr₹1542 Cr₹1452 Cr₹1398 Cr₹1477 Cr₹1567 Cr₹1448 Cr₹1441 Cr₹1365 Cr₹1398 Cr₹1319 Cr₹1226 Cr
₹2109 Cr₹2068 Cr₹1954 Cr₹1730 Cr₹1709 Cr₹1679 Cr₹1626 Cr₹1554 Cr₹1571 Cr₹1588 Cr₹1554 Cr₹1535 Cr₹1507 Cr₹1730 Cr₹1501 Cr₹1475 Cr₹1354 Cr₹1381 Cr₹1210 Cr₹1418 Cr₹1347 Cr₹1291 Cr₹1375 Cr₹1327 Cr₹1058 Cr₹1229 Cr₹1191 Cr₹1914 Cr₹1850 Cr₹2123 Cr₹1982 Cr₹1909 Cr₹1729 Cr₹1976 Cr₹1733 Cr₹1415 Cr₹1331 Cr₹1412 Cr₹1232 Cr₹1151 Cr₹1157 Cr₹1350 Cr₹1136 Cr₹1204 Cr₹1191 Cr₹1362 Cr₹1350 Cr₹1329 Cr₹1415 Cr₹1395 Cr₹1287 Cr₹1252 Cr₹1205 Cr₹1243 Cr₹1121 Cr₹1022 Cr
₹268 Cr₹363 Cr₹310 Cr₹351 Cr₹302 Cr₹357 Cr₹297 Cr₹311 Cr₹266 Cr₹286 Cr₹254 Cr₹252 Cr₹178 Cr₹224 Cr₹155 Cr₹232 Cr₹204 Cr₹244 Cr₹200 Cr₹344 Cr₹379 Cr₹381 Cr₹496 Cr₹353 Cr₹183 Cr₹455 Cr₹414 Cr₹481 Cr₹444 Cr₹351 Cr₹522 Cr₹454 Cr₹447 Cr₹481 Cr₹420 Cr₹313 Cr₹344 Cr₹316 Cr₹337 Cr₹345 Cr₹372 Cr₹295 Cr₹309 Cr₹328 Cr₹329 Cr₹247 Cr₹181 Cr₹137 Cr₹135 Cr₹241 Cr₹235 Cr₹260 Cr₹228 Cr₹225 Cr₹261 Cr₹266 Cr
₹54 Cr₹57 Cr₹56 Cr₹50 Cr₹49 Cr₹53 Cr₹56 Cr₹61 Cr₹71 Cr₹73 Cr₹71 Cr₹66 Cr₹62 Cr₹56 Cr₹51 Cr₹42 Cr₹40 Cr₹40 Cr₹37 Cr₹35 Cr₹35 Cr₹43 Cr₹46 Cr₹46 Cr₹48 Cr₹47 Cr₹49 Cr₹72 Cr₹73 Cr₹62 Cr₹53 Cr₹54 Cr₹51 Cr₹72 Cr₹77 Cr₹66 Cr₹69 Cr₹80 Cr₹98 Cr₹80 Cr₹83 Cr₹99 Cr₹89 Cr₹92 Cr₹91 Cr₹79 Cr₹86 Cr₹96 Cr₹63 Cr₹65 Cr₹65 Cr₹67 Cr₹65 Cr₹59 Cr₹54 Cr₹57 Cr
₹86 Cr₹176 Cr₹94 Cr₹190 Cr₹155 Cr₹206 Cr₹131 Cr₹145 Cr₹500 Cr-₹57 Cr₹88 Cr₹89 Cr₹27 Cr-₹103 Cr₹10 Cr₹39 Cr₹69 Cr₹104 Cr₹70 Cr₹209 Cr₹256 Cr₹241 Cr₹343 Cr₹222 Cr₹54 Cr₹310 Cr₹248 Cr₹292 Cr₹269 Cr-₹40 Cr₹356 Cr₹302 Cr₹286 Cr₹227 Cr₹261 Cr₹168 Cr₹203 Cr₹160 Cr₹166 Cr₹193 Cr₹218 Cr₹69 Cr₹145 Cr₹161 Cr₹168 Cr₹68 Cr₹16 Cr-₹23 Cr-₹20 Cr₹144 Cr₹107 Cr-₹28 Cr-₹16 Cr₹18 Cr₹75 Cr₹194 Cr
₹56 Cr₹119 Cr₹56 Cr₹120 Cr₹103 Cr₹151 Cr₹101 Cr₹103 Cr₹482 Cr-₹65 Cr₹53 Cr₹53 Cr₹7 Cr-₹117 Cr-₹14 Cr₹8 Cr₹47 Cr₹58 Cr₹51 Cr₹144 Cr₹170 Cr₹199 Cr₹313 Cr₹224 Cr₹88 Cr₹260 Cr₹203 Cr₹249 Cr₹185 Cr-₹101 Cr₹268 Cr₹210 Cr₹200 Cr₹152 Cr₹213 Cr₹125 Cr₹144 Cr₹149 Cr₹118 Cr₹144 Cr₹164 Cr₹11 Cr₹122 Cr₹125 Cr₹130 Cr₹43 Cr-₹5 Cr-₹88 Cr₹9 Cr₹108 Cr₹156 Cr-₹79 Cr-₹47 Cr-₹24 Cr₹40 Cr₹158 Cr

Share Price Live Stats

Open (₹)919.00
Volume (₹)4.98 L
High (₹)930.00
Upper Circuit1,089.45
Low (₹)901.20
Lower Circuit726.35
Prev Close907.90
52W High (₹)1,184.80
Price924.50
52W Low (₹)786.05

Share Market Cap & Key Ratios Overview

M.Cap (₹)14436.40 Cr
Div. Yield (%)0.55
PE Ratio41.00
Debt to Equity0.46
Price to Book1.82
Book Value447.70
EPS (TTM)22.11
Face Value1.00
ROE (%)5.97

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
JUBLPHARMANSE
LTP
1W Low
1W High
Market cap (₹)
1899-21 (-1.09%)
1895
1984.80
4,56,833Cr
9100-139 (-1.50%)
9087
9467
2,45,426Cr
4857-193 (-3.82%)
4823
5066
1,87,320Cr
1120-71 (-5.96%)
1120
1187
1,13,217Cr
1385-38.5 (-2.70%)
1375.50
1426.10
1,12,212Cr
1840-98.5 (-5.08%)
1811.70
1949
1,01,155Cr
2110-61.5 (-2.83%)
2100.60
2192
97,626Cr
2327.9-55 (-2.31%)
2317
2419.20
96,859Cr
1151-27 (-2.29%)
1151
1179.90
96,406Cr
1653.1+7.8 (0.47%)
1622.60
1717
93,614Cr
924.5+41.85 (4.74%)
864.70
930
14,436Cr

Key Highlights of Jubilant Pharmova Ltd’s P&L

In 2026-03-31, Jubilant Pharmova Ltd reported total revenue of ₹8345.6Cr, compared with ₹7291.3Cr in 2025-03-31, reflecting Jubilant Pharmova Ltd turnover.

Depreciation was ₹440.4Cr and finance costs were ₹211.8Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹614.1Cr in 2026-03-31 as compared to ₹980.6Cr in 2025-03-31.

Net Profit (PAT) was ₹398.5Cr in 2026-03-31 compared with ₹839.4Cr in 2025-03-31.

Earnings per share (EPS) were ₹25.22 in 2026-03-31, compared with ₹53.13 in 2025-03-31.